BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 8758143)

  • 1. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
    Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
    Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
    Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
    Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
    Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
    Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
    Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
    Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
    Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Dullin M; Sulahian A; Garin YJ; Derouin F
    Antimicrob Agents Chemother; 1999 Jan; 43(1):172-4. PubMed ID: 9869587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
    Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
    Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
    J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
    Gramiccia M; Gradoni L; Orsini S
    Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
    Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice.
    Silva SC; Silva DF; Almeida TC; Perasoli FB; da Silva ATP; da Silva GN; Rezende SA
    Parasitol Res; 2018 Sep; 117(9):2881-2893. PubMed ID: 29943317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
    Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
    Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
    Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
    Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.